CNSP vs. TRIB, COCP, RLYB, ERNA, ABP, EDSA, MBRX, UBX, MEIP, and UPXI
Should you be buying CNS Pharmaceuticals stock or one of its competitors? The main competitors of CNS Pharmaceuticals include Trinity Biotech (TRIB), Cocrystal Pharma (COCP), Rallybio (RLYB), Eterna Therapeutics (ERNA), Abpro (ABP), Edesa Biotech (EDSA), Moleculin Biotech (MBRX), Unity Biotechnology (UBX), MEI Pharma (MEIP), and Upexi (UPXI). These companies are all part of the "pharmaceutical products" industry.
CNS Pharmaceuticals vs.
Trinity Biotech (NASDAQ:TRIB) and CNS Pharmaceuticals (NASDAQ:CNSP) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation, media sentiment, earnings and community ranking.
In the previous week, Trinity Biotech had 2 more articles in the media than CNS Pharmaceuticals. MarketBeat recorded 6 mentions for Trinity Biotech and 4 mentions for CNS Pharmaceuticals. CNS Pharmaceuticals' average media sentiment score of 0.22 beat Trinity Biotech's score of -0.60 indicating that CNS Pharmaceuticals is being referred to more favorably in the news media.
CNS Pharmaceuticals has a consensus target price of $25.00, suggesting a potential upside of 1,949.18%. Given CNS Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe CNS Pharmaceuticals is more favorable than Trinity Biotech.
CNS Pharmaceuticals has lower revenue, but higher earnings than Trinity Biotech. Trinity Biotech is trading at a lower price-to-earnings ratio than CNS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
CNS Pharmaceuticals has a net margin of 0.00% compared to Trinity Biotech's net margin of -34.39%.
79.0% of Trinity Biotech shares are owned by institutional investors. Comparatively, 14.0% of CNS Pharmaceuticals shares are owned by institutional investors. 8.2% of Trinity Biotech shares are owned by company insiders. Comparatively, 0.1% of CNS Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Trinity Biotech received 287 more outperform votes than CNS Pharmaceuticals when rated by MarketBeat users. However, 70.59% of users gave CNS Pharmaceuticals an outperform vote while only 69.79% of users gave Trinity Biotech an outperform vote.
Trinity Biotech has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500. Comparatively, CNS Pharmaceuticals has a beta of 2.67, suggesting that its share price is 167% more volatile than the S&P 500.
Summary
CNS Pharmaceuticals beats Trinity Biotech on 9 of the 16 factors compared between the two stocks.
Get CNS Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CNSP and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CNS Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:CNSP) was last updated on 5/21/2025 by MarketBeat.com Staff
Buy CNSP Stock Free CNSP Stock Alerts